PTC Therapeutics (NASDAQ:PTCT)

CAPS Rating: 2 out of 5

Results 1 - 3 of 3

Recs

0
Member Avatar superstar (99.73) Submitted: 3/2/2016 9:35:15 AM : Outperform Start Price: $11.42 PTCT Score: -41.73

Severely undervalued, cash on hand, plus pipeline, easily places share value north of $10. 10,000 shares at $5.80. Real purchase this morning-- pre-market. Time frame uncertain, but looking for shares to break much higher with time.

Recs

1
Member Avatar TSIF (99.95) Submitted: 2/23/2016 1:00:25 PM : Outperform Start Price: $12.38 PTCT Score: -47.15

I'm not sure which is more mysterious...

1. That the company hasn't chimed in yet with a plan of action well into the day it's stock cratered from an FDA "refuse to file" letter.

2. That the company was inept enough to file an application that was so badly lacking.

3. That the stock was ever $78 this year for any reason, considering the test/trial limitations to validate and the question of valuation if the improvement does exist, but is marginal.

Given that the treatment is approved in Europe, though they are much less restrictive, the company has cash, the company has support of some non-profits (but this is mostly due to the fact that there are NO drugs to treat Duchenne muscular dystrophy at all), and that speculators and Fools are always standing by to jump in.....this might be worth a CAPS upthumb....(actually might be worth a handful of options...still debating if I have any funds in my purely speculation, okay with losing it all fund....it's been batting about 50/50 this year.

SPEC play, not recommended for general consumption....whichever way this goes and it could go much lower will occur in the new 72 hours..meaning my 7 day hold is locked past any catalyst.

Recs

4
Member Avatar noataluren (< 20) Submitted: 5/28/2014 12:49:44 PM : Underperform Start Price: $23.38 PTCT Score: +75.99

As a former PTC employee, this recommendation for conditional approval is a joke. None of the data are strong. The improvement for the 40 mg/kg/day dose over placebo was significant (after eliminating 2 patients whose baseline data was faulty) in the DMD trial, however the results from the higher 80 mg/kg/day dose almost perfectly matched the placebo. Moreover, the CF Phase 3 trial was not only negative on the primary endpoint, but also on pretty much all the secondaries. Most importantly, the endpoint that was the primary in the Phase 2 studies in CF, used to show proof of concept, was highly nonsignificant in the Phase 3 study. Don't be surprised to see this one land flat on its face.

Results 1 - 3 of 3

Featured Broker Partners